ISPOR Europe 2024

Join us at ISPOR Europe.

We’re proudly exhibiting at this November’s ISPOR Europe in Barcelona, Spain. Our experts are looking forward to connecting at our booth, in live meetings, at our poster sessions, and more.

Where to find us.

1307

Our booth

You can find our exhibition space at #1307. Check out the ISPOR conference map for details.

20+

Poster Presentations

Engage with our experts at our featured posters for deeper dive into our work.

2

Featured Posters

One of our posters will be featured as a Top 5% abstract finalist, and another will be highlighted in a live podium presentation. Be on the look out!

The poster titles you might want to visit.

Don’t miss out on the poster sessions throughout the duration of the conference for a chance to view some of our recent work across a range of topics.

Here are some of our titles

Demonstrating the value of digital solutions in market access (Barbier S, Tournier C, Morin M, Virely N, Doghri O, Tardu J, Loomba A, Klein L, Boyce L, Sivignon M) (Mon 1030am-130pm)
Cost Effectiveness in Nanomedicines: A Small Step for Research, a Giant Leap in Value (Klimushkin N, Meunier A, Hardern C, Farrington J) (Mon 1030am-130pm)
Transporting Evidence Across Borders: A Targeted Review of the Use and Acceptability of Non-Local Data to Derive Real-World External Control Arms in Submissions to NICE (Robertshaw E, Keenan C, Leahy T, McStravick M, Sammon C, Turner A) (Mon 1030am-130pm)
From French Early Access to Reimbursement: A Comparison of Early Access Prices and List Prices (Hanna E, Dimassi M, Remuzat C, Francois C) (Mon 4-7pm)
How Is Evidence on Comparative Efficacy and Safety Presented in Japanese HTA Submissions: A Targeted Literature Review (McStravick M, Onishi Y, Kiyabu G, Turner A, Robertshaw E, Keenan C, Ikeda S( (Mon 4-7pm)
Contradictory Phase in the French Economic Appraisal: Overview and Impact on CEESP Conclusions (Doghri O, Cheylac C, Supiot R, Sivignon M) (Tue 1030-130pm)
Investigators’ Choice Comparator Arms: A Review of Their Use and Appraisal in Health Technology Assessments (McStravick M, Sammon C, Turner A) (Tue 1030-130pm)
Adverse Event (AE) Management Costs Associated With Immune Checkpoint Inhibitors (ICI) Approved for Various Advanced or Metastatic Cancers in the US (Ranjan S, Gandhi J, Mothe R, Werwath T, Ameen R, Kk M, Sagar K, Potluri R) (Tue 1030-130pm)
Recent Developments in European Voluntary Cross-Border Collaborations in Joint HTA, Drug Pricing, Procurement, and Readiness for EU HTA Implementation (Skowron R, Grioui N, Koćwin A, Dimassi M, Cork D, Remuzat C, Francois C) (Tue 1030-130pm)
Innovative Contracts: A Solution to Manage the ATMPs Associated Uncertainty (Cheylac C, Francois C, Sivignon M, Sellami R) (Tue 4-7pm)
How Are National HTA Bodies Preparing for the Implementation of the EU HTA Regulation? (Remuzat C, Koćwin A, Grioui N, Dimassi M, Cork D, Francois C) (Wed 9-1130am)
QoL Data in CAR-T Cost-Effectiveness Analysis (CEA) in France: What to Use? (Sellami R, Sivignon M) (Wed 9-1130am)
Cost-effectiveness of empagliflozin in the treatment of patients with chronic kidney disease in France (Supiot R, Tardu J, Virely N, Sivignon M, Chollet J, Uster A, Lévy P, Massy Z) (Mon 1030am-130pm)
Key considerations for cost-effectiveness modelling in heart failure with mildly reduced or preserved ejection fraction (Hardern C, Simmons H, Crossan C, McEwan P, Sullivan SD, Mernagh P, Folkerts K) (Mon 1030am-130pm)
Assessing the Potential Public Health Impact of the mRNA-Based Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345, With a Broad Vaccination Campaign Among Older Adults in the United Kingdom: Modelling Study (Dronova M, Tytuła A, Janusz Z, Ghaswalla P, Sebestyén-Balogh O, Joshi K) (Mon 1030am-130pm)
Real-World US Optum Claims Database Study of Pre- and Post-Relapse Costs and Health Care Resource Utilization (HCRU) in Patients With High-Risk Localized or Locally Advanced Prostate Cancer (HR-LPC/LAPC) Who Relapsed (Siebert U, Bjartell A, Nair S, Lin X, De Solda F, Potluri R, McCarthy SA, Mundle SD, McCallion J, Jahn B) (Mon 4pm-7pm)
A Time Trade-Off Study to Develop Health-Related Utility Data for the Impact of Geographic Atrophy on Patients (Intorcia M, Hill S, Moor H, Sarda SP, Oluboyede Y) (Mon 4pm-7pm)
Environmental Impact of Switching from Daily to Weekly Basal Insulin Administration in France (Bellier L, Antier C, Soggiu M, Virely N, Laporte L, Sivignon M, Kind B) (Mon 4pm-7pm)
Fondaparinux: A Cost-Saving Alternative to Low-Molecular-Weight Heparins for Venous Thromboembolic Event Prevention/Treatment and Acute Coronary Syndrome Treatment (Austrup H, Giudici B, Cork D, Bellomo C) (Mon 4pm-7pm)
Estimating the Public Health Impact of Pediatric Vaccination Programs on Invasive Pneumococcal Disease in France (Fiévez S, Wilson M, Blanc E, Beillat M, Bellier L, Perdrizet J) (Mon 4pm-7pm)
A Targeted Literature Review to Assess the Impact of Environmental and Socio-Demographic Factors on the Onset of Type 1 Diabetes (Allali N, Petrie J, Grandhomme A, Vataire AL, Miry B, Bahloul A) (Tue 1030am-130pm)
Cost-Effectiveness Analysis of Liso-Cel in the Treatment of Patients With Refractory or Relapsed Large B-Cell Lymphoma Within 12 Months (LBCL RR≤12) Eligible for Autologous Hematopoietic Stem Cell Transplant (ASCT) in France (Thieblemont C, Colrat F, Sellami R, Sivignon M, Branchoux S, Petel A, De Pouvourville G) (Tue 4pm-7pm)
Long and Complex Superficial Femoral Artery (SFA) Lesion Treatments in France: An Analysis of the French Nationwide Claims Database (Tournier C, Gouëffic Y, Leboucher C, Chatellier G, de Léotoing L) (Wed 9am-1130am)

Bridging Science & Strategy^TM.

We are a leading scientific and strategic consulting partner that helps the global life science community make confident, impactful decisions and develop bespoke solutions that support bringing life-changing innovations to clinicians and patients.

Find expertise across core practice domain.

Learn more

Market Access & HTA Strategy

HE Modeling & PRO Evidence Generation

Systematic Review, RWE Generation & Biostatistics

Latest Insights.

View All Insights

Navigating the Joint Clinical Assessment (JCA) with a strategic market access partner

Navigate the JCA launch with Putnam's expert strategies. Unlock optimal market access with PICO-driven insights, evidence plans & regulatory synergy.

Recent Trends in Rare Diseases

Putnam experts share observations on recent global trends in the rare disease space and recommend strategies to maximize opportunities.

Preparing for the effects of the IRA on payer contracting

The Inflation Reduction Act (IRA) is likely to prompt a range of second-order effects on the pharmaceutical industry...

Integrating market access considerations into biopharmaceutical asset investment decisions: Common pain points and best practices

Best practices for navigating challenges in integrating market access into investment decision-making.

Leaders attending.

Yoshie Onishi

Principal

Centers of Excellence

AI at Putnam

Open roles

We'll see you at ISPOR EU 2024

Join us at ISPOR Europe.

Where to find us.

1307

Our booth

20+

Poster Presentations

2

Featured Posters

The poster titles you might want to visit.

Here are some of our titles .st0{fill:#fff}

Bridging Science & StrategyTM.

Find expertise across core practice domain.

Market Access & HTA Strategy

HE Modeling & PRO Evidence Generation

Systematic Review, RWE Generation & Biostatistics

Latest Insights.

Navigating the Joint Clinical Assessment (JCA) with a strategic market access partner

Recent Trends in Rare Diseases

Preparing for the effects of the IRA on payer contracting

Integrating market access considerations into biopharmaceutical asset investment decisions: Common pain points and best practices

Leaders attending.

Yoshie Onishi

Clement Francois

Marine Sivignon

Aurelie Meunier

Catriona Crossan

Mariia Dronova

Yemi Oluboyede

Sarah Hill

Alex Turner

Sylvaine Barbier

Ulrike Kuchenbecker

Ravi Potluri

Mateusz Nikodem

Cécile Rémuzat

Remco op den Kelder

Eric Auger

Joanne Evason

Louise McEntee-Richardson

Get in touch.

Here are some of our titles

Bridging Science & Strategy^TM.